⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 22, 2022Leukemia & lymphoma/Leukemia and lymphomaOpen Access

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study

View Full Paper

Ask AI

Bookmark

Share

Abstract

= 14). DARA + CyBorD followed by daratumumab maintenance was well tolerated and achieved deep, durable responses in NDMM and RMM.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yimer et al. (2022) studied this question.

synapsesocial.com/papers/6a21bec6151425ce3dc002c4 https://doi.org/10.1080/10428194.2022.2076847

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumabLate-Phase Clinical Trial · 2020 · 124 citations
2Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79Early-Phase Clinical Trial · 2014 · 226 citations
3Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaCohort Study · 2017 · 1,005 citations
4Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaEarly-Phase Clinical Trial · 2012 · 452 citations
5Cyclophosphamide–Bortezomib–Dexamethasone Compared with Bortezomib–Dexamethasone in Transplantation-Eligible Patients with Newly Diagnosed Multiple MyelomaRetrospective Study · 2020 · 9 citations